MaxCyte appoints Amanda Murphy as CFO

Prior to joining MaxCyte, Murphy specialised in gene therapy, gene editing and cell therapy equity research for both burgeoning private and established public healthcare companies - most recently as managing director of BTIG.

Holtz, who will remain on MaxCyte's board of directors, will retain certain elements of his former role - including overseeing accounting and budgeting/forecasting and supporting key business operations.

Chief executive Doug Doerfler said: "We are collectively witnessing the beginning of cell and gene therapies' impact on revolutionising medical treatment and saving human lives, and Amanda's wealth of experience - her deep understanding of the financial community and her unique, insightful, strategic view of the cell therapy sector - will support the continued development and expansion of MaxCyte's contribution in this space."

As of 0935 BST, MaxCyte shares were down 3.03% at 320.0p.